Elina Tester serves as President & CEO of ABG LAB. She has more than 15-years experience in developing and bringing to life cutting-edge technologies first with Beilis Development, DermaLabs and now, ABG LAB.
In the early 2000’s, she was the principal force behind the research, development and commercialization of the first stem-cell-activating peptide for topical cosmetic use Polypeptide 1, known also as “Amatokin”.
Since 2005, she has worked closely with Dr. Boris Petrikovsky, Senior Science Advisor for ABG LAB, to develop and launch breakthrough anti-aging injection technologies and treatments such as
Meso-Wharton P199™, Meso-Xanthin F199™.
She has worked perilously to introduce new injection and topical skincare technologies to the market with great success, such as the new Meso C71 Complex, with the revolutionary fat-dissolving C71 Peptide, along with many other anti-aging topical facial rejuvenation treatments.
Dr. Elina Tester holds a degree in Molecular Biology from Long Island University.
Boris Petrikovsky, M.D., Ph.D. is a world-renowned, board-certified OB/GYN physician specializing in fetal medicine and surgery. He serves as a member of the editorial board of the Journal of Neonatal Intensive Care.
Dr. Petrikovsky’s major research interests are fetal medicine, prenatal diagnosis, fetoscopy, fetal cardiology, OB/ GYN sonography, and invasive OB/GYN procedures.
He was the first in the world to perform in-utero platelet transfusion, in the rare case of a congenital fetal problem, with excellent result.
Dr. Petrikovsky pioneered a new technique of transcervical endoscopy (patent #51in8), which allows for direct visualization and treatment of the fetus when membranes are ruptured. He has published over 100 peer-reviewed articles and ten book chapters, as well as Fetal Disorders, a best selling textbook on fetal medicine and treatment. He is the recipient of the Recognition Award of the Brooklyn Gynecologic Society, the Howard Levine M.D. Science Award from the Obstetrical Society of Boston, the Bristol-Myers Squib/Mead Johnson Traveling Fellowship, and the Award of the Italian Society of Perinatal Medicine.
As a brilliant laboratory scientist and innovator, David Ott has been the Chief Technology Development Officer for Beilis Development and Director of R&D for ABG Lab since their inception. After completing a graduate degree in Biology from Penn State University, David has excelled in creating dynamic new topical skin and hair products, as well as a keen eye for new anti-aging technologies.
After playing a vital role in helping guide the R&D of Polypeptide 1, the first stem cell activating peptide,
he has assisted Dr. Elina Tester in the development of Meso-Xanthin F199 and the new Meso C71 Complex. His achievements and record speak for itself and paramount to the accomplishments put forth at ABG Lab. A vital force in the research arm of ABG Lab as it pioneers revolutionary anti-aging technologies.
Louis Rinaldi brings to ABG LAB the culmination of multiple decades of bright and fruitful experience in dietary supplements topical skincare and anti-aging technologies.
After serving as Chief Cosmetic Officer for a multi-million dollar Fortune 500 company, he has brought solid experience and expertise in marketing, regulatory affairs and media communications.
His strong and successful career path includes a key role in marketing, global media communications and in launching internationally known products, including the Strivectin skincare brand, Hylexin, Lumedia
and Amatokin, the first stem cell activating face cream.
Serving as the Chief Operating Officer at ABG Lab has allowed us to build upon his great wisdom and communication channels, to which he has helped us bring numerous formidable anti-aging technologies to market.